RAKTA THERAPEUTICS, INC.

Biotech · Private

Small molecule therapeutics targeting parasite heme transport pathways for treatment of leishmaniasis and other neglected tropical diseases

Grants
$702K
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Selective inhibitors of Heme Transporters as Antiparasitic Agents$350,126
Federal grantDepartment of Health and Human Services · Phase I · Selective inhibitors of Heme Transporters as Antiparasitic Agents$352,188
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1944Iviva Medical—$2.0M
1945PanTheryx, Inc.—$84M
1946Vero Biotech Inc.—$84M
1947RAKTA THERAPEUTICS, INC.——
1948IGF Oncology, LLC—$2.4M
1949GENECENTRIX INC.——
1950SCALED MICROBIOMICS, LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.